• EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.
    • Schmidt MK, Kelly JE, Brédart A, Cameron DA, de Boniface J, Easton DF, Offersen BV, Poulakaki F, Rubio IT, Sardanelli F, Schmutzler R, Spanic T, Weigelt B, Rutgers EJT.
    • Eur J Cancer. 2022 Dec 13 [2023 Mar];181:79-91. doi: 10.1016/j.ejca.2022.11.036. Epub ahead of print.
    • Prophylactic Radical Fimbriectomy with Delayed Oophorectomy in Women with a High Risk of Developing an Ovarian Carcinoma: Results of a Prospective National Pilot Study.
    • Leblanc E, Narducci F, Ferron G, Mailliez A, Charvolin JY, El Hajj H, Guyon F, Fourchotte V, Lambaudie E, Crouzet A, Fouche Y, Gouy S, Collinet P, Caquant F, Pomel C, Golfier F, Vaini-Cowen V, Fournier I, Salzet M, Tresch E, Probst A, Lemaire AS, Le Deley MC, Hudry D.
    • Cancers (Basel). 2023 Feb 10;15(4):1141. doi: 10.3390/cancers15041141.

    Related:

    •• Identifier: NCT01608074: Radical Fimbriectomy for Young BRCA Mutation Carriers (Fimbriectomy). (ClinicalTrials.gov . Accessed 2023 Feb 12.)

    • Uptake and Effectiveness of Risk-Reducing Surgeries in Unaffected Female BRCA1 and BRCA2 Carriers: A Single Institution Experience in the Czech Republic.
    • Zimovjanova M, Bielcikova Z, Miskovicova M, Vocka M, Zimovjanova A, Marian Rybar M, Novotny J, Petruzelka L.
    • Cancers (Basel). 2023 Feb 8;15(4):1072. doi: 10.3390/cancers15041072.
    • Factors Influencing Residual Glandular Breast Tissue after Risk-Reducing Mastectomy in Genetically Predisposed Individuals Detected by MRI Mammography.
    • Dietzel F, Kolberg L, Vesper AS, Hoffmann J, Nestle-Krämling C, Zwiefel K, Friebe V, Sawicki LM, Bruckmann NM, Jannusch K, Morawitz J, Antoch G, Fehm TN, Kirchner J, Mohrmann S.
    • Cancers (Basel). 2023 Jan 29;15(3):829. doi: 10.3390/cancers15030829.
    • Long-Term Non-Cancer Risks in People with BRCA Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review.
    • Nitschke AS, Abreu do Valle H, Dawson L, Kwon JS, Hanley GE.
    • Cancers (Basel). 2023 Jan 24;15(3):711. doi: 10.3390/cancers15030711.
    • Survival Outcomes in Women with Unilateral, Triple-Negative, Breast Cancer Correlated with Contralateral Prophylactic Mastectomy.
    • Fasano GA, Bayard S, Chen Y, Marti J, Simmons R, Swistel A, Bensenhaver J, Davis M, Newman L.
    • Ann Surg Oncol. 2023 Jan 21. doi: 10.1245/s10434-022-13056-0. Epub ahead of print.
    • Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?
    • Loizzi V, Dellino M, Cerbone M, Arezzo F, Chiariello G, Lepera A, Cazzato G, Cascardi E, Damiani GR, Cicinelli E, Cormio G.
    • Hormones (Athens). 2023 Jan 13. doi: 10.1007/s42000-022-00427-1. Epub ahead of print.
    • Review
    • The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
    • Loizzi V, Dellino M, Cerbone M, Arezzo F, Cazzato G, Damiani GR, Pinto V, Silvestris E, Kardhashi A, Cicinelli E, Cascardi E, Cormio G.
    • Int J Mol Sci. 2023 Jan 1;24(1):764. doi: 10.3390/ijms24010764.
    • Contralateral Prophylactic Mastectomy among Women with Pathogenic Variants in BRCA1/2: Overall Survival, Racial, and Ethnic Differences.
    • Makhnoon S, Gutierrez Barrera AM, Bassett R, Afrough A, Bedrosian I, Arun BK.
    • Breast J. 2022 Dec 31. doi: 10.1155/2022/1447545. Online ahead of print.
    • Effectiveness of Secondary Risk-Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study.
    • Maksimenko J, Rodrigues PP, Nakazawa-Miklaševiča M, Pinto D, Miklaševičs E, Trofimovičs G, Gardovskis J, Cardoso F, Cardoso MJ.
    • JMIR Form Res. 2022 Dec 29;6(12):e37144. doi: 10.2196/37144.
    • The risks of cancer in older women with BRCA pathogenic variants: How far have we come?
    • Metcalfe KA, Gronwald J, Tung NM, McCuaig JM, Eisen A, Elser C, Foulkes WD, Neuhausen SL, Senter L, Moller P, Bordeleau L, Fruscio R, Velsher L, Zakalik D, Olopade OI, Eng C, Pal T, Cullinane CA, Couch FJ, Kotsopoulos J, Sun P, Lubinski J, Narod SA.
    • Cancer. 2022 Dec 26. doi: 10.1002/cncr.34615. Epub ahead of print.
    • BIA-ALCL Epidemiological Findings From a Retrospective Study of 248 Cases Extracted from Relevant Case Reports and Series: A Systematic Review.
    • Di Pompeo FS, Panagiotakos D, Firmani G, Sorotos M.
    • Aesthet Surg J. 2022 Nov 29:sjac312. doi: 10.1093/asj/sjac312. Epub ahead of print.
    • Surgical and Oncologic Outcomes of Robotic and Conventional Nipple-Sparing Mastectomy with Immediate Reconstruction: International Multicenter Pooled Data Analysis.
    • Park HS, Lee J, Lai HW, Park JM, Ryu JM, Lee JE, Kim JY, Marrazzo E, De Scalzi AM, Corso G, Montemurro F, Gazzetta G, Pozzi G, Toesca A.
    • Ann Surg Oncol. 2022 Oct;29(11):6646-6657. doi: 10.1245/s10434-022-11865-x. Epub 2022 May 18.
    • Incidence of Occult Breast Cancer in Carriers of BRCA1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated?
    • Wong SM, Ferroum A, Apostolova C, Alhassan B, Prakash I, Basik M, Boileau JF, Meterissian S, Aleynikova O, Wong N, Foulkes WD.
    • Ann Surg Oncol. 2022 Oct;29(11):6660-6668. doi: 10.1245/s10434-022-11916-3. Epub 2022 May 26.
    • ASO Visual Abstract: Incidence of Occult Breast Cancer in Carriers of BRCA1/2 and Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy-When is Sentinel Lymph Node Biopsy Indicated?
    • Wong SM, Ferroum A, Apostolova C, Alhassan B, Prakash I, Basik M, Boileau JF, Meterissian S, Aleynikova O, Wong N, Foulkes WD.
    • Ann Surg Oncol. 2022 Oct;29(11):6671-6672. doi: 10.1245/s10434-022-12011-3.
    • Prophylactic mastectomy and occult malignancy: Surgical and imaging considerations.
    • Thompson JL, Sinco BR, McCaffrey RL, Chang AE, Sabel MS, Dossett LA, Hughes TM, Jeruss JS.
    • J Surg Oncol. 2022 Sep 7. doi: 10.1002/jso.27088. Epub ahead of print.
    • Surgical Outcome Measures in a Cohort of Patients at High Risk of Breast Cancer Treated by Bilateral Risk Reducing Mastectomy and Breast Reconstruction.
    • Gandhi A, Duxbury P, Clancy T, Lalloo F, Wisely JA, Kirwan CC, Foden P, Stocking K, Howell A, Evans DG.
    • Plast Reconstr Surg. 2022 Sep 1;150(3):496e-505e. doi: 10.1097/PRS.0000000000009383. Epub 2022 Jun 24.
    • Surgical management of BRCA-mutation carriers: A single institution experience.
    • Gentile D, Losurdo A, Sagona A, Zuradelli M, Gatzemeier W, Barbieri E, Testori A, Errico V, Bianchi P, Biondi E, Torrisi R, Santoro A, Tinterri C.
    • Eur J Surg Oncol. 2022 Aug;48(8):1706-1712. doi: 10.1016/j.ejso.2022.04.024. Epub 2022 Apr 30.
    • Satisfaction and Quality of Life of Healthy and Unilateral Diseased BRCA1/2 Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the BREAST-Q Questionnaire.
    • Herold N, Hellmich M, Lichtenheldt F, Ataseven B, Hillebrand V, Wappenschmidt B, Schmutzler RK, Rhiem K.
    • Genes (Basel). 2022 Jul 28;13(8):1357. doi: 10.3390/genes13081357.
    • Study: Risk-reducing ovarian cancer surgery and quality of life.
    • [No author given]
    • FORCE. XRAY. 2022 Jul 26.

    Related:

    Original research:

    Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.

    • Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal.
    • Kotsopoulos J, Lubinski J, Gronwald J, Menkiszak J, McCuaig J, Metcalfe K, Foulkes WD, Neuhausen SL, Sun S, Karlan BY, Eisen A, Tung N, Olopade OI, Couch FJ, Huzarski T, Senter L, Bordeleau L, Singer CF, Eng C, Fruscio R, Pal T, Sun P, Narod SA.
    • Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1351-1358. doi: 10.1158/1055-9965.EPI-21-1196.
    • The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations.
    • Tomiczek-Szwiec J, Szwiec M, Falco M, Cybulski C, Wokolorczyk D, Jakubowska A, Gronwald J, Stawicka M, Godlewski D, Kilar E, Marczyk E, Siolek M, Wisniowski R, Haus O, Sibilski R, Bodnar L, Sun P, Narod SA, Lubinski J, Huzarski T; Polish Breast Cancer Consortium.
    • Br J Cancer. 2022 Jul;127(1):84-91. doi: 10.1038/s41416-022-01770-1. Epub 2022 Mar 7.
    • Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis.
    • Wang Y, Song Z, Zhang S, Wang X, Li P.
    • Eur J Surg Oncol. 2022 Jun;48(6):1209-1216. doi: 10.1016/j.ejso.2022.02.019. Epub 2022 Feb 18.
    • Meta-Analysis
    • Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer.
    • Rhiem K, Auber B, Briest S, Dikow N, Ditsch N, Dragicevic N, Grill S, Hahnen E, Horvath J, Jaeger B, Kast K, Kiechle M, Leinert E, Morlot S, Püsken M, Schäfer D, Schott S, Schroeder C, Siebers-Renelt U, Solbach C, Weber-Lassalle N, Witzel I, Zeder-Göß C, Schmutzler RK.
    • Breast Care (Basel). 2022 Apr;17(2):199-207. doi: 10.1159/000516376. Epub 2021 Jul 19.
    • Surgery and prophylactic surgery in hereditary breast cancer.
    • Morrow M.
    • Breast. 2022 Mar;62 Suppl 1:S63-S66. doi: 10.1016/j.breast.2021.12.010. Epub 2021 Dec 13.
    • Pre-pectoral breast reconstruction: early and long-term safety evaluation of 146 unselected cases of the early pre-pectoral era of a single-institution, including cases with previous breast irradiation and post-mastectomy radiation therapy.
    • Bernini M, Meattini I, Saieva C, Becherini C, Salvestrini V, Visani L, Stocchi G, Bellini C, Lorenzetti V, Sordi S, Nori J, De Benedetto D, Desideri I, Bianchi S, Livi L, Orzalesi L.
    • Breast Cancer. 2022 Mar;29(2):302-313. doi: 10.1007/s12282-021-01314-0. Epub 2021 Nov 14.
    • Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis.
    • Wang C, Lin Y, Zhu H, Zhou Y, Mao F, Huang X, Zhou X, Cao X, Sun Q.
    • Breast Cancer. 2022 Mar;29(2):314-323. doi: 10.1007/s12282-021-01312-2. Epub 2021 Nov 11.
    • Meta-Analysis
    • Earlier decisions on breast and ovarian surgery reduce cancer in women at high risk.
    • Saul H, Gursul D, Cassidy S, Evans G.
    • BMJ. 2022 Feb 15;376:o258. doi: 10.1136/bmj.o258.
    • Research news

    Related:

    Original research:

    Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers.

    • Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2.
    • Samuel D, Diaz-Barbe A, Pinto A, Schlumbrecht M, George S.
    • Cells. 2022 Feb 4;11(3):539. doi: 10.3390/cells11030539.
    • Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers.
    • Marcinkute R, Woodward ER, Gandhi A, Howell S, Crosbie EJ, Wissely J, Harvey J, Highton L, Murphy J, Holland C, Edmondson R, Clayton R, Barr L, Harkness EF, Howell A, Lalloo F, Evans DG.
    • J Med Genet. 2022 Feb;59(2):133-140. doi: 10.1136/jmedgenet-2020-107356. Epub 2021 Feb 10.

    Related:

    Research news:

    Earlier decisions on breast and ovarian surgery reduce cancer in women at high risk.

    • Pregnancy induced hyperplasia of residual breast tissue following risk reducing contralateral mastectomy - simply interesting or a clinically important observation.
    • Pitiyarachchi O, Phillips KA, Friedlander M.
    • Cancer Treat Res Commun. 2022 Jan 1;30:100504. doi: 10.1016/j.ctarc.2021.100504. Epub ahead of print.
    • Metastatic ovarian carcinoma in breast cancer patients during risk-reducing salpingo-oophorectomy: Report of two cases.
    • Shakya P, Bajracharya A, Shrestha S, Kharel S, Maharjan R, Shrestha AK.
    • Ann Med Surg (Lond). 2021 Dec 6;73:103158. doi: 10.1016/j.amsu.2021.103158. eCollection 2022 Jan.
    • Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li-Fraumeni syndrome.
    • Siegel A, Bremer RC, Klein WMP, Savage SA, Loud JT, Khincha PP.
    • Breast Cancer Res Treat. 2022 Jan;191(1):159-167. doi: 10.1007/s10549-021-06410-5. Epub 2021 Oct 15.
    • Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
    • John CS, Fong A, Alban R, Gillen J, Moore KM, Walsh CS, Li AJ, Rimel BJ, Amersi F, Cass I.
    • Gynecol Oncol. 2022 Jan;164(1):202-207. doi: 10.1016/j.ygyno.2021.10.077. Epub 2021 Nov 30.
    • ASO Visual Abstract: How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?
    • Garstka M, Henriquez A, Kelly BN, Webster A, Khubchandani JA, Hughes K, Nguyen A, Oseni T, Specht M, Coopey SB, Gadd MA, Smith BL.
    • Ann Surg Oncol. 2021 Dec;28(Suppl 3):594-595. doi: 10.1245/s10434-021-10583-0.
    • Trend and survival benefit of contralateral prophylactic mastectomy among men with stage I-III unilateral breast cancer in the USA, 1998-2016.
    • Yang Y, Pan L, Shao Z.
    • Breast Cancer Res Treat. 2021 Dec;190(3):503-515. doi: 10.1007/s10549-021-06397-z. Epub 2021 Sep 23.
    • Association of Premenopausal Bilateral Oophorectomy With Cognitive Performance and Risk of Mild Cognitive Impairment.
    • Rocca WA, Lohse CM, Smith CY, Fields JA, Machulda MM, Mielke MM.
    • JAMA Netw Open. 2021 Nov 1;4(11):e2131448. doi: 10.1001/jamanetworkopen.2021.31448.

    Related:

    Commentary:

    Long-term Risk of Cognitive Impairment and Dementia Following Bilateral Oophorectomy in Premenopausal Women-Time to Rethink Policies?

    • What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy.
    • Hickey M, Moss KM, Krejany EO, Wrede CD, Brand A, Kirk J, Symecko HL, Domchek SM, Tejada-Berges T, Trainer A, Mishra GD.
    • Gynecol Oncol. 2021 Oct;163(1):148-154. doi: 10.1016/j.ygyno.2021.07.029. Epub 2021 Jul 24.
    • Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis.
    • Jia Z, Li J, Zhang Y, Wang X, Xing J, Xing Z, Huang X, Liu G, Zhang M, Feng K, Wu J, Wang W, Wang J, Liu J, Wang X.
    • Cancer Cell Int. 2021 Sep 25;21(1):512. doi: 10.1186/s12935-021-02194-2.
    • Implant-based immediate reconstruction in prophylactic mastectomy: is the caudal dermis flap a reliable alternative to synthetic mesh or acellular dermal matrix?
    • Heine N, Hoesl V, Seitz S, Prantl L, Brebant V.
    • Arch Gynecol Obstet. 2021 Sep 23. doi: 10.1007/s00404-021-06244-y. Epub ahead of print.
    • Chirurgie de réduction de risque mammaire et découverte fortuite de cancer : dix ans d’expérience dans un centre de lutte contre le cancer [Prophylactic mastectomy and occult cancer: a ten-year experience at a cancer center].
    • Mangiardi-Veltin M, Chamming's F, Jaffre A, Rousvoal A, Tunon de Lara C, Brouste V, Hoppe S, Sénéchal C.
    • Bull Cancer. 2021 Sep 20:S0007-4551(21)00298-8. French. doi: 10.1016/j.bulcan.2021.05.007. Epub ahead of print.
    • [Article in French]
    • Oncoplastic Mammoplasty with disguised geometric compensation.
    • Paulinelli RR, Ribeiro LFJ, Santos TD, Caires EMS, Pontes MGM, Faria BM, Luz MV, Faria SFC, Freitas-Junior R.
    • Surg Oncol. 2021 Sep 20;39:101660. doi: 10.1016/j.suronc.2021.101660. Epub ahead of print.
    • Surgical Management of Hereditary Breast Cancer.
    • Berger ER, Golshan M.
    • Genes (Basel). 2021 Aug 31;12(9):1371. doi: 10.3390/genes12091371.
    • ASO Author Reflections: Prophylactic Nipple-Sparing Mastectomy as an Effective Risk-Reducing Strategy for BRCA Mutation Carriers.
    • Garstka M, Smith BL.
    • Ann Surg Oncol. 2021 Aug 13. doi: 10.1245/s10434-021-10588-9. Epub ahead of print.
    • Commentary
    • The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1/2 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis.
    • Kershaw V, Hickey I, Wyld L, Jha S.
    • Eur J Obstet Gynecol Reprod Biol. 2021 Aug 8;265:7-17. doi: 10.1016/j.ejogrb.2021.08.001. Epub ahead of print.
    • Review
    • Bilateral salpingo-oophorectomy and breast cancer risk for BRCA1 and BRCA2 mutation carriers: Assessing the evidence.
    • Conduit C, Milne RL, Friedlander ML, Phillips KA.
    • Cancer Prev Res (Phila). 2021 Aug 4:canprevres.0141.2021. doi: 10.1158/1940-6207.CAPR-21-0141. Epub ahead of print.
    • Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers.
    • Stanek K, Zimovjanova M, Suk P, Jonas F, Zimovjanova A, Molitor M, Mestak O.
    • Aesthetic Plast Surg. 2021 Aug 3. doi: 10.1007/s00266-021-02506-x. Epub ahead of print.
    • Surgical management of BRCA pathogenic variant carriers with breast cancer: a recent literature review and current state of the art.
    • Terribile DA, Mason EJ, Murando F, DI Leone A, Sanchez AM, Scardina L, Magno S, Franco A, D'Archi S, Natale M, Lucci Cordisco E, Masetti R, Franceschini G.
    • Minerva Surg. 2021 Aug 2. doi: 10.23736/S2724-5691.21.09009-2. Epub ahead of print.
    • Review
    • Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
    • Steenbeek MP, Harmsen MG, Hoogerbrugge N, de Jong MA, Maas AHEM, Prins JB, Bulten J, Teerenstra S, van Bommel MHD, van Doorn HC, Mourits MJE, van Beurden M, Zweemer RP, Gaarenstroom KN, Slangen BFM, Brood-van Zanten MMA, Vos MC, Piek JMJ, van Lonkhuijzen LRCW, Apperloo MJA, Coppus SFPJ, Massuger LFAG, IntHout J, Hermens RPMG, de Hullu JA.
    • JAMA Oncol. 2021 Aug 1;7(8):1203-1212. doi: 10.1001/jamaoncol.2021.1590.

    Related:

    Identifier: NCT02321228: Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers (TUBA). (ClinicalTrials.gov)

    Research news: Study: Risk-reducing ovarian cancer surgery and quality of life. (FORCE. XRAY.)

    • What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy.
    • Hickey M, Moss KM, Krejany EO, Wrede CD, Domchek SM, Kirk J, Brand A, Trainer A, Mishra GD, Baker FC.
    • Gynecol Oncol. 2021 Aug;162(2):447-453. doi: 10.1016/j.ygyno.2021.05.036. Epub 2021 Jun 8.
    • Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers - an Israeli matched pair study.
    • Perri T, Levin G, Naor-Revel S, Eliassi-Revivo P, Lifshitz D, Friedman E, Korach J.
    • Int J Gynaecol Obstet. 2021 Jul 29. doi: 10.1002/ijgo.13843. Epub ahead of print.
    • Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women.
    • Evans DG, Howell SJ, Gandhi A, van Veen EM, Woodward ER, Harvey J, Barr L, Wallace A, Lalloo F, Wilson M, Hurley E, Lim Y, Maxwell AJ, Harkness EF, Howell A.
    • Breast Cancer Res Treat. 2021 Jul 26. doi: 10.1007/s10549-021-06333-1. Epub ahead of print.
    • Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.
    • Kotoula V, Papadopoulou K, Tikas I, Fostira F, Vrettou E, Chrisafi S, Fountzilas E, Koliou GA, Apostolou P, Papazisis K, Zaramboukas T, Asimaki-Vlachopoulou A, Miliaras S, Ananiadis A, Poulios C, Natsiopoulos I, Tsiftsoglou A, Demiri E, Fountzilas G.
    • Breast Cancer. 2021 Jul 24. doi: 10.1007/s12282-021-01276-3. Epub ahead of print.
    • How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?
    • Garstka M, Henriquez A, Kelly BN, Webster A, Khubchandani JA, Hughes K, Nguyen A, Oseni T, Specht M, Coopey SB, Gadd MA, Smith BL.
    • Ann Surg Oncol. 2021 Jul 22. doi: 10.1245/s10434-021-10445-9. Epub ahead of print.
    • Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients.
    • Woo J, Gwak G, Park I, Bae BN, Lee SK, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Ryu JM.
    • Sci Rep. 2021 Jul 20;11(1):14747. doi: 10.1038/s41598-021-94195-4.
    • BRCA, breast cancer and in vitro fertilization: How should we advise our patients?
    • García-Planells J, Francés BS, Diez-Juan A.
    • Fertil Steril. 2021 Jul 8:S0015-0282(21)00505-7. doi: 10.1016/j.fertnstert.2021.06.011. Epub ahead of print.

    Related:

    Original research:

    Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers.

    • A competing risks model with binary time varying covariates for estimation of breast cancer risks in BRCA1 families.
    • Briollais L.
    • Stat Methods Med Res. 2021 Jul 7:9622802211008945. doi: 10.1177/09622802211008945. Epub ahead of print.
    • Interactions of BRCA1-mutated Breast Cancer Cell Lines with Adipose-derived Stromal Cells (ADSCs).
    • Plangger A, Haslik W, Rath B, Neumayer C, Hamilton G.
    • J Mammary Gland Biol Neoplasia. 2021 Jul 6. doi: 10.1007/s10911-021-09493-4. Epub ahead of print.
    • Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed.
    • Conduit C, Milne RL, Phillips KA.
    • JAMA Oncol. 2021 Jul 1. doi: 10.1001/jamaoncol.2021.2037. Epub ahead of print.
    • Letter, Comment

    Related:

    Letter, Reply:

    Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed-Reply.

    Related:

    Original research:

    Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.

    • An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool.
    • Kotsopoulos J, Kim SJ, Armel S, Bordeleau L, Foulkes WD, McKinnon W, Panchal S, Cohen SA, Sun S, Sun P, McKetton L, Troyer AK, Narod SA.
    • Cancer. 2021 Jun 2. doi: 10.1002/cncr.33654. Epub ahead of print.
    • Risk-Reducing Mastectomy and Reconstruction Following Prophylactic Breast Irradiation: Hope Sustained.
    • Ben David MA, Evron E, Rasco AF, Shai A, Corn BW.
    • Cancers (Basel). 2021 May 30;13(11):2694. doi: 10.3390/cancers13112694.
    • BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art.
    • Sekine M, Nishino K, Enomoto T.
    • Cancers (Basel). 2021 May 23;13(11):2562. doi: 10.3390/cancers13112562.
    • Hormone Replacement Therapy After Gynaecological Malignancies: a Review Article.
    • Sourouni M, Kiesel L.
    • Geburtshilfe Frauenheilkd. 2021 May;81(5):549-554. doi: 10.1055/a-1390-4353. Epub 2021 May 20.
    • Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.
    • Huber D, Seitz S, Kast K, Emons G, Ortmann O.
    • J Cancer Res Clin Oncol. 2021 Apr 22. doi: 10.1007/s00432-021-03629-z. Epub ahead of print.
    • Management of patients with BRCA mutation from the point of view of a breast surgeon.
    • Riis ML.
    • Ann Med Surg (Lond). 2021 Apr 16;65:102311. doi: 10.1016/j.amsu.2021.102311.
    • A Case Report of Breast Implant-Associated Anaplastic Large-Cell Lymphoma in a PALB2 Mutation-Positive Woman.
    • Bonev V.
    • Am Surg. 2021 Apr 15:31348211011056. doi: 10.1177/00031348211011056. Epub ahead of print.
    • Case report
    • Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
    • Choi YH, Terry MB, Daly MB, MacInnis RJ, Hopper JL, Colonna S, Buys SS, Andrulis IL, John EM, Kurian AW, Briollais L.
    • JAMA Oncol. 2021 Apr 1;7(4):585-592. doi: 10.1001/jamaoncol.2020.7995.

    Related:

    Letter, Comment:

    Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed.

    Letter, Reply:

    Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed-Reply.

    • Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability.
    • Scheepens JCC, van 't Veer L, Esserman L, Belkora J, Mukhtar RA.
    • Breast. 2021 Apr;56:61-69. doi: 10.1016/j.breast.2021.02.003. Epub 2021 Feb 10.
    • Delayed unilateral hematoma after reconstructive and aesthetic breast surgery with implants in Asian patients: two case reports.
    • Lee JH, Hong HK, Kim WH, Kim HJ, Lee J, Park HY, Yang JD, Lee JS.
    • Gland Surg. 2021 Apr;10(4):1515-1522. doi: 10.21037/gs-20-854.
    • Understanding Breast Implant Risks.
    • Spittal K.
    • FORCE. XRAY. 2021 Mar 30.
    • Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.
    • Ložar T, Žgajnar J, Perhavec A, Blatnik A, Novakovic S, Krajc M.
    • Eur J Surg Oncol. 2021 Mar 26:S0748-7983(21)00393-0. doi: 10.1016/j.ejso.2021.03.248. Epub ahead of print.
    • Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
    • Michaelson-Cohen R, Gabizon-Peretz S, Armon S, Srebnik-Moshe N, Mor P, Tomer A, Levy-Lahad E, Paluch-Shimon S.
    • Eur J Cancer. 2021 Mar 16;148:95-102. doi: 10.1016/j.ejca.2021.02.007. Epub ahead of print.
    • Survival from breast cancer in women with a BRCA2 mutation by treatment.
    • Evans DG, Phillips KA, Milne RL, Fruscio R, Cybulski C, Gronwald J, Lubinski J, Huzarski T, Hyder Z, Forde C, Metcalfe K, Senter L, Weitzel J, Tung N, Zakalik D, Ekholm M, Sun P, Narod SA; kConFab Investigators, Polish Hereditary Breast Cancer Consortium, Hereditary Breast Cancer Clinical Study Group.
    • Br J Cancer. 2021 Feb 18. doi: 10.1038/s41416-020-01164-1. Epub ahead of print.
    • Post-mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high-risk breast cancer patients.
    • Kanana N, Ben David MA, Nissan N, Yagil Y, Shalmon A, Halshtok O, Gotlieb M, Faermann R, Klang E, Samoocha D, Yassin M, Davidson T, Zippel D, Madorsky Feldman D, Friedman E, Kaidar-Person O, Sklair Levy M.
    • Breast J. 2021 Feb 11. doi: 10.1111/tbj.14190. Epub ahead of print.
    • Nipple Sparing Mastectomy as a Risk-Reducing Procedure for BRCA-Mutated Patients.
    • Rocco N, Montagna G, Criscitiello C, Nava MB, Privitera F, Taher W, Gloria A, Catanuto G.
    • Genes (Basel). 2021 Feb 10;12(2):253. doi: 10.3390/genes12020253.
    • Prophylactic Surgery in the BRCA+ Patient: Do Women Develop Breast Cancer While Waiting?
    • Macadam SA, Slater K, Cheifetz RE, Jansen L, Chia S, Brasher PMA, Bovill ES.
    • Curr Oncol. 2021 Jan 25;28(1):702-715. doi: 10.3390/curroncol28010069.
    • Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer.
    • Vasconcelos de Matos L, Fernandes L, Louro P, Plácido A, Barros M, Vaz F.
    • Curr Oncol. 2021 Jan 14;28(1):485-490. doi: 10.3390/curroncol28010050.
    • Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers.
    • Stjepanovic N, Lubinski J, Moller P, Randall Armel S, Foulkes WD, Tung N, Neuhausen SL, Kotsopoulos J, Sun P, Sun S, Eisen A, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Breast Cancer Res Treat. 2021 Jan 10. doi: 10.1007/s10549-020-06072-9. Epub ahead of print.
    • In Response to "Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations".
    • Narod SA, Giannakeas V.
    • J Clin Oncol. 2020 Dec 20;38(36):4352. doi: 10.1200/JCO.20.02253. Epub 2020 Oct 30.

    Related:

    Letter, Comment:

    Reply to S. A. Narod et al.

    Original research:

    Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations.

    • Nipple-sparing mastectomy: A review of outcomes at a single institution.
    • Woodward S, Willis A, Lazar M, Berger AC, Tsangaris T.
    • Breast J. 2020 Nov;26(11):2183-2187. doi: 10.1111/tbj.14088. Epub 2020 Nov 2.
    • Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
    • Fong A, Cass I, John C, Gillen J, Moore KM, Gangi A, Walsh C, Li AJ, Rimel BJ, Karlan BY, Amersi F.
    • Am Surg. 2020 Oct;86(10):1243-1247. doi: 10.1177/0003134820964208. Epub 2020 Oct 26.
    • Quality of Life after Bilateral and Contralateral Prophylactic Mastectomy with Implant Reconstruction.
    • Klapdor R, Weiß C, Kuehnle E, Kohls F, von Ehr J, Philippeit A, Hille-Betz U.
    • Breast Care (Basel). 2020 Oct;15(5):519-526. doi: 10.1159/000505449. Epub 2020 Jan 24.
    • Clinicopathological Features and Outcomes in Individuals with Breast Cancer and ATM, CHEK2, or PALB2 Mutations.
    • Bergstrom C, Pence C, Berg J, Partain N, Sadeghi N, Mauer C, Pirzadeh-Miller S, Gao A, Li H, Unni N, Syed S.
    • Ann Surg Oncol. 2020 Sep 29. doi: 10.1245/s10434-020-09158-2. Epub ahead of print.
    • Cardiovascular Prevention in Individuals at High Risk of Developing Cancer.
    • Oren O, Kopecky SL, Blumenthal RS, Gersh BJ, Yang EH.
    • JACC CardioOncol. 2020 Sep 15;2(3):527-531. doi: 10.1016/j.jaccao.2020.07.002.
    • [In Situ Ductal Carcinoma with Hereditary Breast and Ovarian Cancer Syndrome in a Patient Who Received Contralateral Risk-Reducing Mastectomy-A Case Report].
    • Kosaka Y, Kikuchi M, Nishimiya H, Katoh H, Kawaguchi R, Araki N, Shimazu M, Tsumura H, Waraya M, Takada F, Sengoku N, Sangai T.
    • Gan To Kagaku Ryoho. 2020 Sep;47(9):1387-1389. Japanese.
    • Case report. [Article in Japanese]
    • Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis.
    • Chen J, Bae E, Zhang L, Hughes K, Parmigiani G, Braun D, Rebbeck TR.
    • JNCI Cancer Spectr. 2020 Apr 23 [eCollection 2020 Aug.];4(4):pkaa029. doi: 10.1093/jncics/pkaa029.
    • Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.
    • Silva Filho ALD, Carvalho GM, Sena LC, Gomes LPG, Valério MFH, Martins RIL, Cândido EB.
    • Rev Assoc Med Bras (1992). 2020 Aug;66(8):1134-1138. doi: 10.1590/1806-9282.66.8.1134.
    • Secondary Angiosarcoma With C-MYC Amplification Following Prophylactic Bilateral Mastectomy and Autologous Breast Reconstruction: Report of a Case and Review of the Literature.
    • Webb C, Partain N, Koduru P, Hwang H, Sarode VR.
    • Int J Surg Pathol. 2020 Jun 18:1066896920930100. doi: 10.1177/1066896920930100. Epub ahead of print.
    • Case report
    • Contralateral breast cancer and tumor recurrence in BRCA1/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy.
    • Allué Cabañuz M, Domingo Bretón M, Chóliz Ezquerro J, Arribas Del Amo MD, Güemes Sánchez AT.
    • Cir Esp. 2020 Jun 3:S0009-739X(20)30115-9. English, Spanish. doi: 10.1016/j.ciresp.2020.04.008. Epub ahead of print.
    • [Article in English, Spanish.]
    • Risk Management for BRCA1/BRCA2 mutation carriers without and with breast cancer.
    • Mainor CB, Isaacs C.
    • Curr Breast Cancer Rep. 2020 Jun;12(2):66-74. doi: 10.1007/s12609-019-00350-2. Epub 2020 Feb 17.
    • Review
    • Increased prevalence of BRCA1/2 mutations in women with macro-textured breast implants and anaplastic large cell lymphoma of the breast.
    • De Boer M, Hauptmann M, Hijmering NJ, van Noesel CJM, Rakhorst HA, Meijers-Heijboer HE, Boer JP, van der Hulst RR, De Jong D, van Leeuwen FE.
    • Blood. 2020 May 26:blood.2019004498. doi: 10.1182/blood.2019004498. Epub ahead of print.
    • Letter
    • Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer.
    • Valero MG, Moo TA, Muhsen S, Zabor EC, Stempel M, Pusic A, Gemignani ML, Morrow M, Sacchini V.
    • Br J Surg. 2020 May 20. doi: 10.1002/bjs.11616. Epub ahead of print.
    • Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
    • Stjepanovic N, Villacampa G, Nead KT, Torres-Esquius S, Melis GG, Nathanson KL, Teule A, Brunet J, Y Cajal TR, Llort G, Dienstmann R, Rue M, Domchek SM, Balmaña J.
    • Eur J Cancer. 2020 Apr 20;132:53-60. doi: 10.1016/j.ejca.2020.03.009. [Epub ahead of print]
    • Bilateral Paget's Disease of the Breast in a Patient with CHEK2 Mutation.
    • Owusu-Brackett N, Menon PD, Nazarullah A, Jatoi I, Elmi M.
    • Eur J Breast Health. 2020 Apr 1;16(2):152-154. doi: 10.5152/ejbh.2020.5568. eCollection 2020 Apr.
    • Occult disease in reduction mammoplasties and prophylactic mastectomies.
    • Nomikos A, Husain EA, Graham AD.
    • Breast J. 2020 Apr;26(4):691-696. doi: 10.1111/tbj.13512. Epub 2019 Aug 25.
    • Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?
    • Mills KA, Joshi TV, West L, Kuznicki M, Kent L, Hokenstad AN, Cripe JC, Woolfolk C, Senter L, Bakkum-Gamez JN, Wenham RM, Cohn DE, Bae-Jump V, Thaker PH.
    • Gynecol Oncol. 2020 Mar 3. pii: S0090-8258(20)30179-7. doi: 10.1016/j.ygyno.2020.02.033. [Epub ahead of print]
    • Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
    • Mavaddat N, Antoniou AC, Mooij TM, Hooning MJ, Heemskerk-Gerritsen BA; GENEPSO, Noguès C, Gauthier-Villars M, Caron O, Gesta P, Pujol P, Lortholary A; EMBRACE, Barrowdale D, Frost D, Evans DG, Izatt L, Adlard J, Eeles R, Brewer C, Tischkowitz M, Henderson A, Cook J, Eccles D; HEBON, van Engelen K, Mourits MJE, Ausems MGEM, Koppert LB, Hopper JL, John EM, Chung WK, Andrulis IL, Daly MB, Buys SS; kConFab Investigators, Benitez J, Caldes T, Jakubowska A, Simard J, Singer CF, Tan Y, Olah E, Navratilova M, Foretova L, Gerdes AM, Roos-Blom MJ, Van Leeuwen FE, Arver B, Olsson H, Schmutzler RK, Engel C, Kast K, Phillips KA, Terry MB, Milne RL, Goldgar DE, Rookus MA, Andrieu N, Easton DF; IBCCS; kConFab; BCFR.
    • Breast Cancer Res. 2020 Jan 16;22(1):8. doi: 10.1186/s13058-020-1247-4.
    • Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer Who Are Genetic Carriers, Have a Strong Family History or Are just Young at Presentation.
    • Teoh V, Tasoulis MK, Gui G.
    • Cancers (Basel). 2020 Jan 6;12(1). pii: E140. doi: 10.3390/cancers12010140.
    • Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
    • Solsky I, Chen J, Rebbeck TR.
    • Gynecol Oncol. 2020 Jan 6. pii: S0090-8258(19)31695-6. doi: 10.1016/j.ygyno.2019.11.036. [Epub ahead of print]
    • Increased Overall Mortality Even after Risk Reducing Surgery for BRCA-Positive Women in Western Sweden.
    • Öfverholm A, Einbeigi Z, Wigermo A, Holmberg E, Karsson P.
    • Genes (Basel). 2019 Dec 16;10(12). pii: E1046. doi: 10.3390/genes10121046.
    • Sexual function, menopausal symptoms, depression and cancer worry in women with BRCA mutations.
    • Powell CB, Alabaster A, Le A, Stoller N, Armstrong MA, Raine-Bennett T.
    • Psychooncology. 2019 Oct 26. doi: 10.1002/pon.5253. [Epub ahead of print]
    • Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199).
    • Mai PL, Miller A, Gail MH, Skates S, Lu K, Sherman ME, Ioffe OB, Rodriguez G, Cohn DE, Boggess J, Rutherford T, Kauff ND, Rader JS, Phillips KA, DiSilvestro PA, Olawaiye AB, Ridgway MR, Greene MH, Piedmonte M, Walker JL.
    • JNCI Cancer Spectr. 2019 Oct 10;4(1):pkz075. doi: 10.1093/jncics/pkz075. eCollection 2020 Feb.

    Related:

    Commentary:

    Preventing Breast Cancer in High-Risk Women: Is There Still a Role for Oophorectomy?

    • Oncological Safety of Lipofilling in Healthy BRCA Carriers After Bilateral Prophylactic Mastectomy: A Case Series.
    • Quoc CH, Dias LPN, Braghiroli OFM, Martella N, Giovinazzo V, Piat JM.
    • Eur J Breast Health. 2019 Oct 1;15(4):217-221. doi: 10.5152/ejbh.2019.5013. eCollection 2019 Oct.
    • Risk-reducing mastectomy in BRCA carriers: survival is not the issue.
    • Neven P, Punie K, Wildiers H, Willers N, Van Ongeval C, Van Buggenhout G, Legius E.
    • Breast Cancer Res Treat. 2019 Sep 20. doi: 10.1007/s10549-019-05440-4. [Epub ahead of print]
    • Letter, Comment

    Related:

    Letter, Reply:

    Risk-reducing mastectomy in BRCA mutation carriers: survival is one of the issues-author's reply.

    Original Research:

    Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.

    • Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
    • Evans DG, Howell SJ, Howell A.
    • Fam Cancer. 2019 Aug 23. doi: 10.1007/s10689-019-00142-8. [Epub ahead of print]

    Related:

    Original Research:

    Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.

    • Use of Mammographic Measurements to Predict Complications After Nipple-Sparing Mastectomy in BRCA Mutation Carriers.
    • Park KU, Weiss A, Rosso K, Yi M, Hunt K, Kuerer H, Hanson SE, Candelaria R, Tevis S, Thompson A.
    • Ann Surg Oncol. 2019 Aug 9. doi: 10.1245/s10434-019-07704-1. [Epub ahead of print]
    • A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre.
    • Petelin L, Hossack L, Mitchell G, Liew D, Trainer AH, James PA.
    • Value Health. 2019 Aug;22(8):854-862. doi: 10.1016/j.jval.2019.03.008. Epub 2019 May 17.
    • Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
    • Chang J, Seng S, Yoo J, Equivel P, Lum SS.
    • Ann Surg Oncol. 2019 Jul 24. doi: 10.1245/s10434-019-07595-2. [Epub ahead of print]
    • Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.
    • Heemskerk-Gerritsen BAM, Jager A, Koppert LB, Obdeijn AI, Collée M, Meijers-Heijboer HEJ, Jenner DJ, Oldenburg HSA, van Engelen K, de Vries J, van Asperen CJ, Devilee P, Blok MJ, Kets CM, Ausems MGEM, Seynaeve C, Rookus MA, Hooning M.
    • Breast Cancer Res Treat. 2019 Jul 13. doi: 10.1007/s10549-019-05345-2. [Epub ahead of print]

    Related:

    Commentary:

    Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?

    Letter, Comment:

    Risk-reducing mastectomy in BRCA carriers: survival is not the issue.

    Letter, Reply:

    Risk-reducing mastectomy in BRCA mutation carriers: survival is one of the issues-author's reply.

    • How Safe Is Hormone Replacement Therapy After Risk-Reducing Salpingo-oophorectomy in Women With BRCA Mutations?
    • Markman M.
    • Medscape Oncology. 2019 Jun 14.

    Related:

    Original research:

    Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.

    • Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
    • Kotsopoulos J, Lubinski J, Lynch HT, Tung N, Armel S, Senter L, Singer CF, Fruscio R, Couch F, Weitzel JN, Karlan B, Foulkes WD, Moller P, Eisen A, Ainsworth P, Neuhausen SL, Olopade O, Sun P, Gronwald J, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Breast Cancer Res Treat. 2019 Jun;175(2):443-449. doi: 10.1007/s10549-019-05162-7. Epub 2019 Feb 12.
    • Women's health 2019: Osteoporosis, breast cancer, contraception, and hormone therapy.
    • Moreno AC, Sahni SK, Smith TL, Batur P.
    • Cleve Clin J Med. 2019 Jun;86(6):400-406. doi: 10.3949/ccjm.86a.18130.
    • Residual glandular tissue (RGT) in BRCA1/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies.
    • Grinstein O, Krug B, Hellmic M, Siedek F, Malter W, Burke C, Schmutzler R, Maintz D, Rhiem K.
    • Surg Oncol. 2019 Jun;29:126-133. doi: 10.1016/j.suronc.2019.04.009. Epub 2019 May 3.
    • Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer.
    • Sávolt Á, Cserni G, Lázár G, Maráz R, Kelemen P, Kovács E, Győrffy B, Udvarhelyi N, Vörös A, Ormándi K, Mátrai Z.
    • Eur J Surg Oncol. 2019 May 16. pii: S0748-7983(19)30454-8. doi: 10.1016/j.ejso.2019.05.016. [Epub ahead of print]
    • Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan.
    • Nomura H, Sekine M, Yokoyama S, Arai M, Enomoto T, Takeshima N, Nakamura S.
    • Int J Clin Oncol. 2019 May 4. doi: 10.1007/s10147-019-01456-4. [Epub ahead of print]
    • Who should get a contralateral prophylactic mastectomy for breast cancer?
    • Bedrosian I, Parker PA, Brewster AM.
    • Cancer. 2019 May 1;125(9):1400-1403. doi: 10.1002/cncr.31915. Epub 2019 Jan 15.
    • Case report, review
    • Differences between screen-detected and interval breast cancers among BRCA mutation carriers.
    • Pilewskie M, Zabor EC, Gilbert E, Stempel M, Petruolo O, Mangino D, Robson M, Jochelson MS.
    • Breast Cancer Res Treat. 2019 May;175(1):141-148. doi: 10.1007/s10549-018-05123-6. Epub 2019 Jan 23.
    • Analysis of Outcomes in Patients With BRCA1/2 Breast Cancer Mutations Treated With Accelerated Partial Breast Irradiation (APBI).
    • Ahmed F, Christos PJ, Singh P, Parashar B, Wernicke AG.
    • Am J Clin Oncol. 2019 Apr 9. doi: 10.1097/COC.0000000000000542. [Epub ahead of print]
    • Multidisciplinary management of CDH1 germinal mutation and prophylactic management hereditary lobular breast cancer: A case report.
    • Mirandola S, Pellini F, Granuzzo E, Lorenzi M, Accordini B, Ulgelmo M, Invento A, Lombardi D, Caldana M, Pollini GP.
    • Int J Surg Case Rep. 2019 Apr 5;58:92-95. doi: 10.1016/j.ijscr.2019.03.053. [Epub ahead of print]
    • Evolving indications and long-term oncological outcomes of risk-reducing bilateral nipple-sparing mastectomy.
    • Grobmyer SR, Pederson HJ, Valente SA, Al-Hilli Z, Radford D, Djohan R, Yetman R, Eng C, Crowe JP.
    • BJS Open. 2018 Nov 26;3(2):169-173. doi: 10.1002/bjs5.50117. eCollection 2019 Apr.
    • Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2
    • Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, Swisher EM.
    • Gynecol Oncol. 2019 Apr;153(1):192-200. doi: 10.1016/j.ygyno.2018.12.014. Epub 2019 Jan 17.
    • Review

    Related:

    Commentary: How Safe Is Hormone Replacement Therapy After Risk-Reducing Salpingo-oophorectomy in Women With BRCA Mutations? (Medscape Oncology)

    • Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.
    • Vermeulen RFM, Korse CM, Kenter GG, Brood-van Zanten MMA, Beurden MV.
    • Climacteric. 2019 Mar 25:1-9. doi: 10.1080/13697137.2019.1582622. [Epub ahead of print]
    • Review
    • Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy.
    • Menkiszak J, Chudecka-Głaz A, Cymbaluk-Płoska A, Celewicz A, Kojs Z, Szajda M, Świniarska M, Bedner R, Jurczak A, Celewicz M, Cieszyńska M, Lubiński J, Gronwald J.
    • Hered Cancer Clin Pract. 2019 Mar 14;17:10. doi: 10.1186/s13053-019-0109-5. eCollection 2019.
    • Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk.
    • Terry MB, Daly MB, Phillips KA, Ma X, Zeinomar N, Leoce N, Dite GS, MacInnis RJ, Chung WK, Knight JA, Southey MC, Milne RL, Goldgar D, Giles GG, Weideman PC, Glendon G, Buchsbaum R, Andrulis IL, John EM, Buys SS, Hopper JL.
    • J Natl Cancer Inst. 2019 Mar 1;111(3):331-334. doi: 10.1093/jnci/djy182.

    Related:

    Press: Oophorectomy to Reduce Ovarian-cancer Risk Not Tied to Breast-cancer Risk. (Medscape Oncology)

    • Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers.
    • Stewart ME, Knisely AT, Sullivan MW, Ring KL, Modesitt SC.
    • Gynecol Oncol Rep. 2019 Feb 1;28:18-22. doi: 10.1016/j.gore.2019.01.010. eCollection 2019 May.
    • Risk Reduction and Survival Benefit of Risk-Reducing Salpingo-oophorectomy in Hereditary Breast Cancer: Meta-analysis and Systematic Review.
    • Xiao YL, Wang K, Liu Q, Li J, Zhang X, Li HY.
    • Clin Breast Cancer. 2019 Feb;19(1):e48-e65. doi: 10.1016/j.clbc.2018.09.011. Epub 2018 Oct 4.
    • Prophylactic Versus Therapeutic Mastectomy: A Contemporary Analysis of the ACS-NSQIP Database.
    • Hendrix RJ, Lee C, Friedrich AK, Rouanet E, Larkin AC, LaFemina J.
    • Clin Breast Cancer. 2019 Jan 31. pii: S1526-8209(19)30050-3. doi: 10.1016/j.clbc.2019.01.008. [Epub ahead of print]
    • Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion.
    • Domchek SM.
    • JAMA. 2019 Jan 1;321(1):27. doi: 10.1001/jama.2018.18942.
    • Review, Commentary
    • High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan.
    • Yamauchi H, Okawa M, Yokoyama S, Nakagawa C, Yoshida R, Suzuki K, Nakamura S, Arai M.
    • Breast Cancer Res Treat. 2018 Dec;172(3):679-687. doi: 10.1007/s10549-018-4953-1. Epub 2018 Sep 10.
    • Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study.
    • Vermeulen RFM, van Beurden M, Gaarenstroom KN, Teunis T, Kieffer JM, Aaronson NK, Kenter GG, Korse CM.
    • Climacteric. 2018 Dec;21(6):574-580. doi: 10.1080/13697137.2018.1512965. Epub 2018 Oct 8.
    • Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
    • Marchetti C, De Felice F, Boccia S, Sassu C, Di Donato V, Perniola G, Palaia I, Monti M, Muzii L, Tombolini V, Benedetti Panici P.
    • Crit Rev Oncol Hematol. 2018 Dec;132:111-115. doi: 10.1016/j.critrevonc.2018.09.018. Epub 2018 Oct 3.
    • Review
    • Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
    • Straub MM, Podoll MB, David SN, Wiesner GL, Desouki MM.
    • Ann Diagn Pathol. 2018 Oct;36:28-30. doi: 10.1016/j.anndiagpath.2018.06.003. Epub 2018 Jun 27.
    • Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study.
    • Minig L, Cabrera S, Oliver R, Couso A, Rubio MJ, Iacoponi S, Martin-Salamanca MB, Carballo-Rastrilla S, Cádenas-Rebollo JM, García-Garcia A, Gil-Ibáñez B, Juan-Fita MJ, Patrono MG.
    • Clin Transl Oncol. 2018 Oct;20(10):1337-1344. doi: 10.1007/s12094-018-1865-9. Epub 2018 Apr 5.
    • Risk management adherence following genetic testing for hereditary cancer syndromes: a Singaporean experience.
    • Courtney E, Chin XW, Yuen J, Li ST, Chen Y, Allen JC Jr, Tan V, Lim GH, Ngeow J.
    • Fam Cancer. 2018 Oct;17(4):621-626. doi: 10.1007/s10689-018-0071-9.
    • Hormone therapy and breast cancer risk after ovary removal in women with a BRCA1 mutation.
    • [No author given]
    • FORCE. XRAYS. 2018 Sep 7.

    Related:

    Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.

    • Surgery for BRCA, TP53 and PALB2: a literature review.
    • Song CV, Teo SH, Taib NA, Yip CH.
    • Ecancermedicalscience. 2018 Aug 29;12:863. doi: 10.3332/ecancer.2018.863. eCollection 2018.
    • Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    • Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO.
    • Cochrane Database Syst Rev. 2018 Aug 24;8:CD012464. doi: 10.1002/14651858.CD012464.pub2.
    • Meta-Analysis, Review
    • Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
    • Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • JAMA Oncol. 2018 Aug 1;4(8):1059-1065. doi: 10.1001/jamaoncol.2018.0211.

    Related:

    Research News: Hormone therapy and breast cancer risk after ovary removal in women with a BRCA1 mutation. (FORCE, XRAYS)

    Commentary, Video: Menopausal Hormone Therapy and Risk for Breast Cancer in BRCA1 Mutation Carriers. (Medscape)

    • The risk of stroke after bilateral salpingo-oophorectomy at hysterectomy for benign diseases: A nationwide cohort study.
    • Lai JC, Chou YJ, Huang N, Chen HH, Wang KL, Wang CW, Shen IH, Chang HC.
    • Maturitas. 2018 Aug;114:27-33. doi: 10.1016/j.maturitas.2018.05.007. Epub 2018 May 19.
    • Mortality and Risk of Cancer After Prophylactic Bilateral Oophorectomy in Women With a Family History of Cancer.
    • Abildgaard J, Ahlström MG, Daugaard G, Nielsen DL, Tønnes Pedersen A, Lindegaard B, Obel N.
    • JNCI Cancer Spectrum. 2018 Jul 1;2(3):pky034. doi: 10.1093/jncics/pky034.
    • Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK.
    • Long J, Evans TG, Bailey D, Lewis MH, Gower-Thomas K, Murray A.
    • Breast J. 2018 Jul;24(4):580-585. doi: 10.1111/tbj.12978. Epub 2017 Dec 29.
    • Prophylactic salpingo-oophorectomy & surgical menopause for inherited risks of cancer: the need to identify biomarkers to assess the theoretical risk of premature coronary artery disease.
    • Batulan Z, Maarouf N, Shrivastava V, O'Brien E.
    • Womens Midlife Health. 2018 Apr 27;4:7. doi: 10.1186/s40695-018-0037-y. eCollection 2018.
    • Risk-reducing mastectomy for the prevention of primary breast cancer.
    • Carbine NE, Lostumbo L, Wallace J, Ko H.
    • Cochrane Database Syst Rev. 2018 Apr 5;4:CD002748. doi: 10.1002/14651858.CD002748.pub4.
    • Review, Meta-Analysis

    Related:

    Summary: Women should be aware of their true risk of developing breast cancer and the limitations of current evidence when considering risk-reducing mastectomy. (Cochrane Library)

    • Does oophorectomy reduce breast cancer mortality for BRCA mutation carriers after breast cancer?
    • Jacobson M, Narod SA.
    • Expert Rev Anticancer Ther. 2018 Apr;18(4):305-306. doi: 10.1080/14737140.2018.1438891. Epub 2018 Feb 16.
    • Commercially Available Lifestyle Modification Program Decreases Inflammatory Biomarkers in BRCA1/2+ Breast Cancer Survivors.
    • Sturgeon KM, Foo W, Schmitz KH/
    • Cancer Epidemiol Biomarkers Prev. 2018 Mar;27(3):357-357. doi: 10.1158/1055-9965.EPI-18-0063.
    • Conference abstract
    • Breast tissue density change after oophorectomy in BRCA mutation carrier patients using visual and volumetric analysis.
    • Lecler A, Dunant A, Delaloge S, Wehrer D, Moussa T, Caron O, Balleyguier C.
    • Br J Radiol. 2018 Feb;91(1083):20170163. doi: 10.1259/bjr.20170163. Epub 2018 Jan 5.
    • Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk.
    • Vreemann S, Gubern-Mérida A, Schlooz-Vries MS, Bult P, van Gils CH, Hoogerbrugge N, Karssemeijer N, Mann RM.
    • Radiology. 2018 Feb;286(2):443-451. doi: 10.1148/radiol.2017170458. Epub 2017 Oct 16.
    • The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study.
    • Câmara S, Pereira D, André S, Mira B, Vaz F, Oom R, Marques JC, Leal de Faria J, Rodrigues Dos Santos C.
    • Int J Breast Cancer. 2018 Jan 1;2018:1426369. doi: 10.1155/2018/1426369. eCollection 2018.
    • Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    • Soenderstrup IMH, Laenkholm AV, Jensen MB, Eriksen JO, Gerdes AM, Hansen TVO, Kruse TA, Larsen MJ, Pedersen IS, Rossing M, Thomassen M, Ejlertsen B.
    • Acta Oncol. 2018 Jan;57(1):95-101. doi: 10.1080/0284186X.2017.1398415. Epub 2017 Nov 22.
    • The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
    • Giannakeas V, Narod SA.
    • Breast Cancer Res Treat. 2018 Jan;167(1):263-267. doi: 10.1007/s10549-017-4476-1. Epub 2017 Sep 15.
    • Multi-institutional Evaluation of Women at High Risk of Developing Breast Cancer.
    • Hermel DJ, Wood ME, Chun J, Rounds T, Sands M, Schwartz S, Schnabel FR.
    • Clin Breast Cancer. 2017 Oct;17(6):427-432. doi: 10.1016/j.clbc.2017.04.005. Epub 2017 Apr 14.
    • Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.
    • Ricciardi E, Tomao F, Aletti G, Bazzurini L, Bocciolone L, Boveri S, Landoni F, Lapresa MT, Maruccio M, Parma G, Peccatori F, Petrella MC, Zanagnolo V, Colombo N, Maggioni A.
    • Anticancer Res. 2017 Sep;37(9):5241-5248.
    • Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers.
    • Havrilesky LJ, Moss HA, Chino J, Myers ER, Kauff ND.
    • Gynecol Oncol. 2017 Jun;145(3):549-554. doi: 10.1016/j.ygyno.2017.03.025. Epub 2017 Apr 6.
    • Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
    • McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.
    • Gynecol Oncol. 2017 May;145(2):346-351. doi: 10.1016/j.ygyno.2017.02.032. Epub 2017 Mar 14.
    • The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review.
    • Siyam T, Ross S, Campbell S, Eurich DT, Yuksel N.
    • BMC Womens Health. 2017 Mar 21;17(1):22. doi: 10.1186/s12905-017-0370-6.
    • STIC-ing with what we know.
    • Chen LM.
    • Gynecol Oncol. 2016 Nov;143(2):227-228. doi: 10.1016/j.ygyno.2016.10.007.
    • Editorial
    • Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers.
    • Zakhour M, Danovitch Y, Lester J, Rimel BJ, Walsh CS, Li AJ, Karlan BY, Cass I.
    • Gynecol Oncol. 2016 Nov;143(2):231-235. doi: 10.1016/j.ygyno.2016.08.336. Epub 2016 Sep 9.
    • Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033).
    • Davies KR, Brewster AM, Bedrosian I, Parker PA, Crosby MA, Peterson SK, Shen Y, Volk RJ, Cantor SB.
    • Breast Cancer Res. 2016 Sep 20;18(1):93. doi: 10.1186/s13058-016-0752-y.
    • Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    • Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, Armel S, Karlan B, Foulkes WD, Neuhausen SL, Senter L, Tung N, Weitzel JN, Eisen A, Metcalfe K, Eng C, Pal T, Evans G, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • J Natl Cancer Inst. 2016 Sep 6;109(1). pii: djw177. doi: 10.1093/jnci/djw177. Print 2017 Jan.
    • Occult Histopathology and Its Predictors in Contralateral and Bilateral Prophylactic Mastectomies.
    • Mattos D, Gfrerer L, Ling IT, Reish RG, Hughes KS, Halpern EF, Cetrulo C, Colwell AS, Winograd JM, Yaremchuk MJ, Austen WG Jr, Liao EC.
    • Ann Surg Oncol. 2016 Mar;23(3):767-75. doi: 10.1245/s10434-015-4896-2. Epub 2015 Nov 17.
    • Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
    • Podo F, Santoro F, Di Leo G, Manoukian S, de Giacomi C, Corcione S, Cortesi L, Carbonaro LA, Trimboli RM, Cilotti A, Preda L, Bonanni B, Pensabene M, Martincich L, Savarese A, Contegiacomo A, Sardanelli F.
    • Clin Cancer Res. 2016 Feb 15;22(4):895-904. doi: 10.1158/1078-0432.CCR-15-0459. Epub 2015 Oct 26.
    • Contralateral Prophylactic Mastectomy: Factors Predictive of Occult Malignancy or High-Risk Lesion and the Impact of MRI and Genetic Testing.
    • Erdahl LM, Boughey JC, Hoskin TL, Degnim AC, Hieken TJ.
    • Ann Surg Oncol. 2016 Jan;23(1):72-7. doi: 10.1245/s10434-015-4660-7. Epub 2015 Jun 12.
    • Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
    • Basu NN, Ingham S, Hodson J, Lalloo F, Bulman M, Howell A, Evans DG.
    • Fam Cancer. 2015 Dec;14(4):531-8. doi: 10.1007/s10689-015-9825-9.
    • Frequency of diagnosis of cancer or high-risk lesion at operation for pathologic nipple discharge.
    • Dupont SC, Boughey JC, Jimenez RE, Hoskin TL, Hieken TJ.
    • Surgery. 2015 Oct;158(4):988-95. doi: 10.1016/j.surg.2015.05.020. Epub 2015 Aug 1.
    • Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.
    • Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P, Kim-Sing C, Ghadirian P, Karlan B, Eng C, Gilchrist D, Neuhausen SL, Eisen A, Friedman E, Euhus D, Ping S, Narod SA; Hereditary Breast Cancer Study Group.
    • Fam Cancer. 2015 Sep;14(3):383-91. doi: 10.1007/s10689-015-9798-8.
    • Breast cancer after prophylactic mastectomy (bilateral or contralateral prophylactic mastectomy), a clinical entity: presentation, management, and outcomes.
    • Mutter RW, Frost MH, Hoskin TL, Johnson JL, Hartmann LC, Boughey JC.
    • Breast Cancer Res Treat. 2015 Aug;153(1):183-90. doi: 10.1007/s10549-015-3515-z. Epub 2015 Jul 26.
    • Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers.
    • Wu S, Weinstein SP, DeLeo MJ 3rd, Conant EF, Chen J, Domchek SM, Kontos D.
    • Breast Cancer Res. 2015 May 19;17(1):67. doi: 10.1186/s13058-015-0577-0.
    • Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation.
    • Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, Rosen B, Maehle L, Ghadirian P, Cybulski C, Huzarski T, Eisen A, Foulkes WD, Kim-Sing C, Ainsworth P, Tung N, Lynch HT, Neuhausen S, Metcalfe KA, Thompson I, Murphy J, Sun P, Narod SA.
    • J Clin Oncol. 2014 May 20;32(15):1547-53. doi: 10.1200/JCO.2013.53.2820. Epub 2014 Feb 24.

    Related:

    Comment, Editorial:

    A major step forward for BRCA1/2-related cancer risk management.

    Research news: Oophorectomy in women with BRCA1 or BRCA2 mutations. (Lancet Oncology)

    Press: Early Surgery in BRCA1 Carriers Lowers Ovarian Cancer Risk. (Medscape)

    Press: Young women with BRCA1 mutation 'should remove ovaries earlier'. (Medical News Today)

    • Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk.
    • Anton A, Schott S, Kaip G, Rath M, Heil J, Aulmann S, Sinn HP.
    • Arch Gynecol Obstet. 2014 May;289(5):1079-85. doi: 10.1007/s00404-013-3062-y. Epub 2013 Nov 7.
    • Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral.
    • Ingham SL, Sperrin M, Baildam A, Ross GL, Clayton R, Lalloo F, Buchan I, Howell A, Evans DG.
    • Breast Cancer Res Treat. 2013 Dec;142(3):611-8. doi: 10.1007/s10549-013-2765-x. Epub 2013 Nov 20.
    • Increased Proliferative Background in Healthy Women with BRCA1/2 Haploinsufficiency Is Associated with High Risk for Breast Cancer.
    • Nisman B, Kadouri L, Allweis T, Maly B, Hamburger T, Gronowitz S, Peretz T.
    • Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2110-5. doi: 10.1158/1055-9965.EPI-13-0193. Epub 2013 Aug 21.
    • Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.
    • Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, Tilanus-Linthorst MM, Koppert LB, Obdeijn IM, van Deurzen CH, Collée JM, Seynaeve C, Hooning MJ.
    • Ann Oncol. 2013 Aug;24(8):2029-35. doi: 10.1093/annonc/mdt134. Epub 2013 Apr 10.
    • Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.
    • Evans DG, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I, Howell A.
    • Breast Cancer Res Treat. 2013 Jul;140(1):135-42. doi: 10.1007/s10549-013-2583-1. Epub 2013 Jun 20.
    • Pulmonary embolism after abdominal flap breast reconstruction: prediction and prevention.
    • Enajat M, Damen TH, Geenen A, Timman R, van der Hulst RR, Mureau MA.
    • Plast Reconstr Surg. 2013 Jun;131(6):1213-22. doi: 10.1097/PRS.0b013e31828bd35e.
    • Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
    • Møller P, Stormorken A, Jonsrud C, Holmen MM, Hagen AI, Clark N, Vabø A, Sun P, Narod SA, Mæhle L.
    • Breast Cancer Res Treat. 2013 May;139(1):155-61. doi: 10.1007/s10549-013-2540-z. Epub 2013 Apr 25.
    • High-Grade Serous Tumor Arising from Fallopian Tube in a BRCA Mutation Carrier after Prophylactic Oophorectomy.
    • Lorusso D, Di Rocco R, Mancini M, Raspagliesi F.
    • Case Rep Oncol. 2013 Jan;6(1):21-4. doi: 10.1159/000346339. Epub 2013 Jan 9.
    • Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
    • Fakkert IE, Mourits MJ, Jansen L, van der Kolk DM, Meijer K, Oosterwijk JC, van der Vegt B, Greuter MJ, de Bock GH.
    • Cancer Prev Res (Phila). 2012 Nov;5(11):1291-7. doi: 10.1158/1940-6207.CAPR-12-0190. Epub 2012 Sep 25.
    • Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations.
    • de Bruin MA, Kwong A, Goldstein BA, Lipson JA, Ikeda DM, McPherson L, Sharma B, Kardashian A, Schackmann E, Kingham KE, Mills MA, West DW, Ford JM, Kurian AW.
    • Fam Cancer. 2012 Sep;11(3):429-39. doi: 10.1007/s10689-012-9531-9.
    • [Surgical prevention of breast carcinoma in patients with hereditary risk].
    • Dražan L, Veselý J, Hýža P, Kubek T, Foretová L, Coufal O.
    • Klin Onkol. [2012 Aug;]25 Suppl:S78-83.
    • A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.
    • Sigal BM, Munoz DF, Kurian AW, Plevritis SK.
    • Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1066-77. doi: 10.1158/1055-9965.EPI-12-0149. Epub 2012 May 3.
    • Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    • Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, Foulkes WD, Ghadirian P, Tung N, Ainsworth P, Senter L, Karlan B, Eisen A, Eng C, Weitzel J, Gilchrist DM, Blum JL, Zakalik D, Singer C, Fallen T, Ginsburg O, Huzarski T, Sun P, Narod SA.
    • Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1089-96. doi: 10.1158/1055-9965.EPI-12-0201. Epub 2012 May 7.

    Related:

    Comment, Letter:

    Oophorectomy and breast cancer in BRCA mutation carriers--letter.

    • Postoophorectomy Estrogen Use and Breast Cancer Risk.
    • Nichols HB, Trentham-Dietz A, Newcomb PA, Titus LJ, Egan KM, Hampton JM, Visvanathan K.
    • Obstet Gynecol. 2012 Jul;120(1):27-36.

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: hormonal birth control with ATM mutations?

    Comment:

    Post-oophorectomy estrogen use and breast cancer risk.

    • Bilateral oophorectomy, body mass index, and mortality in U.S. women aged 40 years and older.
    • McCarthy AM, Menke A, Ouyang P, Visvanathan K.
    • Cancer Prev Res (Phila). 2012 Jun;5(6):847-54. doi: 10.1158/1940-6207.CAPR-11-0430. Epub 2012 May 3.
    • Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.
    • Finkelman BS, Rubinstein WS, Friedman S, Friebel TM, Dubitsky S, Schonberger NS, Shoretz R, Singer CF, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder C, Garber JE, Schildkraut J, Daly MB, Isaacs C, Pichert G, Neuhausen SL, Couch FJ, van't Veer L, Eeles R, Bancroft E, Evans DG, Ganz PA, Tomlinson GE, Narod SA, Matloff E, Domchek S, Rebbeck TR.
    • J Clin Oncol. 2012 Apr 20;30(12):1321-8. doi: 10.1200/JCO.2011.37.8133. Epub 2012 Mar 19.
    • Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.
    • Cohen JV, Chiel L, Boghossian L, Jones M, Stopfer JE, Powers J, Rebbeck TR, Nathanson KL, Domchek SM.
    • Fam Cancer. 2012 Mar;11(1):69-75. doi: 10.1007/s10689-011-9480-8.
    • Online tool to guide decisions for BRCA1/2 mutation carriers.
    • Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK.
    • J Clin Oncol. 2012 Feb 10;30(5):497-506. doi: 10.1200/JCO.2011.38.6060. Epub 2012 Jan 9.

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: An Online BRCA Positive Decision Guidance Tool.

    Comment:

    Are we ready for online tools in decision making for BRCA1/2 mutation carriers?

    Press: Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers? (Journal of Clinical Oncology)

    Press: Online tool helps those with BRCA mutations understand options. (Medical Xpress)

    • Physician data query (PDQ®) update.
    • [No authors listed]
    • J Natl Cancer Inst. 2012 Feb 8;104(3):176. doi: 10.1093/jnci/djs025. Epub 2012 Jan 23.